Preliminary results show a combination of AstraZeneca and the first component of Sputnik V demonstrate a high immunogenicity profile in clinical study in Azerbaijan, the Russian Direct Investment Fund (RDIF) claimed on Friday.
Meanwhile, in India, the regulator has green-signalled conducting a study on combining the Covishield (AstraZeneca shot made by Serum Institute of India) and Covaxin (Bharat Biotech’s shot) by Christian Medical College (CMC), Vellore.
Experts feel that mixing of vaccines based on two different platforms could trigger a better immune response in the beneficiary. The mix and match approach, known as heterogeneous prime and boost, has been historically